Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis



Status:Archived
Conditions:Psoriasis, Dermatology
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:December 2010
End Date:December 2011

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending, Repeated-Dose Study of the Safety and Pharmacokinetics of Subcutaneous REGN668 in Patients With Moderate-to-Severe Extrinsic Atopic Dermatitis


The purpose of this study is to assess the Safety and Tolerability of REGN668 (how the body
reacts to the drug) compared to placebo (an inert substance) in patients with
moderate-to-severe extrinsic Atopic Dermatitis.



We found this trial at
7
sites
Clinical Trial Facility
Albany, New York
?
mi
from
Albany, NY
Click here to add this to my saved trials
Clinical Trial Facility
Austin, Texas
?
mi
from
Austin, TX
Click here to add this to my saved trials
Clinical Trial Facility
Celebration, Florida
?
mi
from
Celebration, FL
Click here to add this to my saved trials
Clinical Trial Facility
Centralia, Illinois
?
mi
from
Centralia, IL
Click here to add this to my saved trials
Clinical Trial Facility
Medford, Oregon
?
mi
from
Medford, OR
Click here to add this to my saved trials
Clinical Trial Facility
Philadelphia, Pennsylvania
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Clinical Trial Facility
Santa Clara, California 95051
?
mi
from
Santa Clara, CA
Click here to add this to my saved trials